Received May 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
soreness around the injection area; This non-serious case was reported by a nurse via sales rep and described the occurrence of injection site pain in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site pain (received first dose on an unknown date, for tolerance of 1st dose, refer case US2026AMR062888). On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: soreness around the injection area). Rechallenge with Shingrix was positive. The outcome of the injection site pain was not reported. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Linked case(s) involving the same patient:US2026AMR062888 Additional Information: GSK Receipt Date: 07-MAY-2026 The patient was approximately 60 years old. The patient went on to receive the second dose of Shingrix, and her only side effect was soreness around the injection site. The batch number was not provided and we and unable to contact the reporter.; Sender's Comments: US-GSK-US2026AMR062888:1 st dose